1648 results about "Butyrate" patented technology

Described is a method for freshening fabric articles by means of spraying the articles with an aqueous slurry of microcapsules having rupturable melamine-formaldehyde polymeric walls, containing substantive and efficacious functional substances, e.g., malodour counteractants and/or fragrances. The slurry may optionally contain non-confined functional substances, e.g. malodour counteractants and/or fragrances. The method is effective for the deposition of effectively-rupturable malodour suppressant and/or fragrance emitting microcapsules onto fabrics wherein the resulting emitted fragrance activity and/or malodour counteractant activity is long-lasting and where the resulting substantive aroma is aesthetically pleasing over the long period of time for which it is effective. Also described are efficacious and substantive malodour counteractant compositions useful for the aforementioned process containing a malodour composition composed of zinc ricinoleate and at least one of: 1-cyclohexylethan-1-yl butyrate; 1-cyclohexylethan-1-yl acetate; 1-cyclohexylethan-1-ol; 1-(4′-methylethyl)cyclohexylethan-1-yl propionate; and/or 2′-hydroxy-1′-ethyl(2-phenoxy)acetate. In addition, described are efficacious microcapsule slurries useful for the aforementioned process containing microcapsules having melamine-formaldehyde polymeric capsule walls with the microcapsules being in contact with one or more polymeric silicone phospholipids.

The invention discloses a specific nanometer paint of energy-saving environment-protective typed aluminium alloy section bar (door and window), which comprises the following parts: 90-100% filming agent, 0.1-10% hardener, 0.5-8% levelling agent, 0.5-10% nanometer material, 20-50% fill and 10% hollow microball, wherein the filming agent is one or more of epoxy resin, polyester resin, acrylic acid resin, amino resin, phenol resin or alkide resin; the hardener is one or more of dicyandiamide, imidazole, dihydrazide, polybasic carboxylic acid, beta-hydroxyalkyl amide or triglycidol isocyanuric ester hardener; the levelling agent is one or more of polyacrylic resin, siliceous acryl resin, polyvinyl butyral, benzoin, hydrocastor oil, cellulose acetate butyrate or epoxy soy oil; the nanometer material is nanometer zinc oxide; the hollow micro-ball is hollow ceramic microball.

The invention relates to a eubacterium and clostridium preparation and application of the same, in particular to a microecological preparation which is prepared for replenishing butyric acid bacteria and butyric acid produced by intestinal tract by taking single eubacterium, single clostridium or a eubacterium and clostridium composition as a main active composition, and application of the same in treating related diseases through butyric acid production, and belongs to the field of biological medicine.

The invention relates generally to the field of industrial microbiology and butanol production. More specifically, the invention relates methods of reducing 2,3-dihydroxy-2-methyl butyrate (DHMB) in butanol production. DHMB can be reduced by inhibiting the reduction of acetolactate to DHMB, for example, by knocking out enzymes that catalyze the reduction or by removing DHMB during or after fermentation. Yeast strains, compositions, and methods for reducing DHMB and increasing butanol yield are provided.

The invention belongs to the field of medicine, and in particular relates to a medical application of 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-((3-chloro-4-methylphenyl) amino)-4-oxobutanoate in a selective histone lysine-specific demethylase 1 (LSD1) inhibitor, especially the application in anti-tumor medicaments. Pharmacodynamic tests indicate that the 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-((3-chloro-4-methylphenyl) amino)-4-oxobutanoate has a remarkable LSD1 inhibiting effect, and has selectivity to homologous proteins MAO-A (monoamine oxidase-A) and MAO-B.

The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and/or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.

Described are synergistically-effective compositions consisting essentially of zinc ricinoleate or solutions thereof and one or more of the substituted monocyclic organic compounds: 1-cyclohexylethan-1-yl butyrate; 1-cyclohexylethan-1-yl acetate; 1-cyclohexylethan-1-ol; 1-(4′-methylethyl)cyclohexylethan-1-yl propionate; and/or 2′-hydroxy-1′-ethyl(2-phenoxy)acetate and uses of same and compositions containing same for preventing and/or suppressing malodors. Also described for the purpose of application to an inanimate laminar substantially solid surface are malodor-suppressing composition-containing stick articles containing an ester-terminated polyamide or an amide-terminated polyamide structural support polymer in combination with the aforementioned synergistically-effective zinc ricinoleate-substituted monocyclic organic compound composition. Also described is a package for conveniently handling the aforementioned stick article.

The present invention relates to a method for producing optically active 2-(N-substituted aminomethyl)-3-hydroxybutyric acid esters wherein a 2-(N-substituted aminomethyl)-3-oxobutyric acid ester is treated with an enzyme source capable of stereoselectively reducing said ester to the corresponding optically active 2-(N-substituted aminomethyl)-3-hydroxybutyric acid ester having the (2S,3R) configuration. The present invention provides an efficient method for industrially producing optically active 2-(N-substituted aminomethyl)-3-hydroxybutyric acid esters, in particular such compounds having the (2S,3R) configuration, which are useful as intermediates for the production of medicinal compounds, among others.

The invention relates to a total biodegradable non-woven fabric material which is produced by adding 10 to 40 percent of low molecular weight carbon dioxide-cyclohexene oxide copolymer or 10 to 40 percent of high molecular weight poly L-polylactic acid or 10 to 40 percent of poly-hydroxylic butyrate to biodegradable carbon dioxide-propylene oxide or carbon dioxide-epoxy ethane copolymer materials, thus improving the dimensional stability of the carbon dioxide copolymer under high temperature. The number average molecular weight of the carbon dioxide-cyclohexene oxide copolymer is between 4000 and 8000 and the number average molecular weight of the poly L-polylactic acid is above 100,000. By using the carbon dioxide copolymer material of the invention, manufacture can be carried out by adopting a spun-bond method which is commonly used in non-woven fabric manufacturing technique. The obtained non-woven fabrics can maintain dimensional stability at the temperature between 70 DEG C and 75 DEG C, have biodegradation characteristics under the situation of composts or landfill with carbon dioxide and water as degradation end products, and cannot pollute environment when being burnt.

Provided herein are processes for the preparation of (S)-(2R,3R,11bR-3-isobuty-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.

Disposable test strips and a wet chemistry method for measuring each of beta-hydroxybutyrate alone, combined beta-hydroxybutyrate and acetoacetate or total ketone bodies (i.e., beta-hydroxybutyrate, acetoacetate and acetone) in human bodily fluid samples, including but not limited to urine, saliva or sweat are described. The test strips need only be dipped in the sample and can be used by anyone in almost any milieu. Measurement can be made electrochemically, spectrophotometrically, fluorometrically or by comparision to a color standard. Combined acetoacetate and beta-hydroxybutyrate which account for 97-98% of total ketone bodies and may be measured in a cyclic reaction that occurs at pH about 7.0 to about 8.3 with beta-hydroxybutyrate dehydrogenase, (beta-HBD), nicotinamide adenine dinucleotide, a tetrazolium dye precursor and an electron mediator. Using this reaction, false positive results obtained from urine samples taken from patients on sulfhydryl drugs are avoided. beta-HBD from some sources was found to cause false negative results in samples (e.g. urine) containing high chloride content due to chloride inhibition of beta-HBD. Using a simple test for chloride inhibition, it was found that beta-HBD from Alcaligenes is not so inhibited. Using either beta-HBD that is not inhibited by chloride or using 10-20 times the normal concentration of this enzyme eliminates false negatives in samples having substantial chloride content, such as urine, both in the reaction described above and in other reactions disclosed for measuring each of beta-hydroxybutyrate alone, combined beta-hydroxybutyrate and acetoacetate and total ketone bodies, all of which reactions occur in the pH range of about 8.6 to about 9.5.

A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and are also encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced.

The invention discloses application of alcohol dehydrogenase with amino acid sequence disclosed as SEQ ID NO:2 in preparing ethyl (R)-4-chloro-3-hydroxy butyrate from ethyl 4-chloroacetoacetate by asymmetric reduction. By using alcohol dehydrogenase with amino acid sequence disclosed as SEQ ID NO:2 as a catalyst, ethyl 4-chloroacetoacetate as a substrate and NADH (nicotinamide adenine dinucleotide) as a cofactor, asymmetric reduction is carried out to prepare the ethyl (R)-4-chloro-3-hydroxy butyrate. The invention applies the alcohol dehydrogenase with amino acid sequence disclosed as SEQ ID NO:2 in preparing ethyl (R)-4-chloro-3-hydroxy butyrate from ethyl 4-chloroacetoacetate by asymmetric reduction for the first time, and has favorable effect. The enzyme activity is up to 5.6 U/mg, the yield of the substrate is up to 94%, and the enantiomeric excess value of the product is 100%. The yield is high, and the production cost is greatly lowered.

The invention discloses a preparation method of two-dimension nitrogen- and phosphorus-doped graphene. The preparation method particularly includes following steps: adding hydrotalcite to a proper amount of a sodium butyrate solution, stirring the mixture, aging the mixture, adding 4-dimethyl aminopyridine and n-butyl phosphate, stirring the mixture in a constant-temperature water bath at 60-70 DEG C for 6-8 h, separating a precipitation from liquid, washing the precipitation with deionized water for 2-3 times, drying and grinding the precipitation, sieving the precipitation through a sieve being 20-40 in meshes to obtain modified hydrotalcite powder, heating the modified hydrotalcite powder in a vacuum tubular furnace to 400-600 DEG C under a vacuum condition for calcining the powder for 2-4 h, adding the calcined powder to a hydrochloric acid solution, separating the precipitation and finally heating the precipitation to 2000-2500 DEG C under the vacuum condition to perform heat treatment for 3-6 h, and cooling a product to obtain the two-dimension nitrogen- and phosphorus-doped graphene. The preparation method is simple in raw materials and is mild in conditions.

The invention relates to a preparation method of high-content 2-hydroxy-4-(methylthio) butyl calcium. The content of 2-hydroxy-4-(methylthio) butyl calcium prepared by the traditional synthesis method is lower. The preparation method provided by the invention comprises the following steps of: adding 2-hydroxy-4-methionine nitrile with content higher than 99.0% used as a raw material in concentrated HCl (hydrochloric acid) for carrying out hydrolysis reaction; after the reaction is finished, regulating pH with alkali till pH is between 7.8-8.0, cooling, crystallizing and filtering to obtain a 2-hydroxy-4-(methylthio) butyric amide crude product; recrystallizing with water to obtain high-content 2-hydroxy-4-(methylthio) butyric amide; and dissolving the high-content 2-hydroxy-4-(methylthio) butyric amide in water, adding excess Ca(OH)2 and directly hydrolyzing at 80-100 DEG C to generate 2-hydroxy-4-(methylthio) butyl calcium. The yield of the preparation method is very high, and the content of the prepared 2-hydroxy-4-(methylthio) butyl calcium is higher than 99.0%.

The invention provides a synthesis process of carbetocin. The synthesis process comprises the following steps: performing a coupling reaction on Fmoc-Gly-OH with Rink Amide-AM Resin obtained in the first step to obtain Fmoc-Gly-Rink Amide-AM Resin; performing deprotection (20% piperidine) with DBLK to obtain H-Gly-Rink Amide-AM RFesin, and orderly completing the coupling of the H-Gly-Rink Amide-AM Resin with Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ile-OH, Fmoc-Tyr(Me)-OH and tetrachlorobutyric acid until carbetocin linear peptide resin is synthesized; mixing a cracking agent with the carbetocin linear peptide resin obtained in the fourth step to have a cracking reaction, thereby removing the Rink Amide-AM Resin and side chain protecting groups; cyclizing the carbetocin linear crude peptide into a carbetocin crude product, and separating and purifying the carbetocin crude product to obtain the carbetocin. The synthesis process has the advantages that the polymerization side reaction is prevented, the process route is greatly simplified, the production cost is reduced and the synthesis efficiency is improved; in addition, the purity of the finished product is high; in short, the synthesis process is convenient for large-scale production, and meanwhile, advantageous for environmental protection, and has remarkable economic and social benefits.

The invention relates to a nanometer carboxylated polystyrene microsphere with a spacer arm and a preparation method thereof. A nanometer carboxylated polystyrene microsphere A is prepared by taking styrene and acrylic acid as a mixed monomer, taking water as a reaction medium, taking potassium persulfate as an initiator and taking sodium dodecyl sulfate as an emulsifier with an emulsion polymerization method. In the presence of EDC (Ethylidene Dichloride) serving as a coupling agent and Sulfo NHS, 4-aminobutyric acid, 6-amidocaproic acid or 8-aminocaprylic acid is connected to the surface of the microsphere, so that the nanometer carboxylated polystyrene microsphere with the spacer arm is prepared. The spacer arm is introduced into the surface of the nanometer microsphere, so that the steric hindrance of a coupling macromolecule is lowered, the activity and utilization ratio of the macromolecule are increased, and a nonspecific interaction between the macromolecule and the polystyrene microsphere is reduced. Meanwhile, the grain diameter of the microsphere can be adjusted by adjusting the using amount of the emulsifier, the length of the space arm and surface density, so that the nanometer microsphere has a wide application prospect in the fields of immune diagnosis, solid phase extraction and the like when serving as a carrier as well as a template.

The present invention relates to an environmentally friendly shell powder functional coating, a preparation method therefor and uses thereof. The coating comprises: bisphenol A-epon, modified shell powder, vegetable extract, propyl silicone emulsion, a nano additive, a modified organic micro powder agent, a surfactant, dioctylphthalate, 3, 3'-(4-trifluoromethyl methyl)-bi-4-hydroxy coumarin, 2,2,4-amino trimethyl-1,3-isoprene glycol mono iso-butyl methacrylate, butyl acetate, ethanol, trimethylol propane triacrylate, N-ammonia amino ethyl piperazine, polydimethylsiloxane and deionized water. In the present invention, by modification of a variety of components and materials, selection and collocation of specific components and a specific preparation method, the variety of components exert a synergistic effect, so as to make the prepared coating have significant antimicrobial, environmental-cleaning and wear-resisting properties. The coating has a huge application potential and extensive value in industrial production.

The invention belongs to the field of fine organic synthesis. The invention selects the mixture of NaCO3, Ba(OH)2, triethylamine and NaCO3, or the mixture of triethylamine and Ba(OH)2 as a catalyst, and makes use of butyraldehyde and formaldehyde to prepare 2, 2-hydroxymethyl butyric acid under the oxidation of hydrogen peroxide or oxygen through aldol condensation reaction. The invention prepares the 2, 2-hydroxymethyl butyric acid in the alkaline condition, thus the side reaction is less, the yield of the 2, 2-hydroxymethyl butyric acid is higher, and the industrialization of the invention is easy to realize.

The invention relates to the field of biotechnology in the pharmaceutical industry, and discloses the preparation of an immobilized whole-cell catalyst and its application in the synthesis of a Puley intermediate (R)-2-hydroxy-4-phenyl-butyric acid. The recombinant cells containing the D-type lactate dehydrogenase gene and the formate dehydrogenase gene are established and fixed to prepare the immobilized whole cell catalyst. Using this catalyst to synthesize the intermediate (R)-2-hydroxy-4-phenyl-butyric acid of lisinopril, the reaction conditions are mild, the action is specific, and there are no by-products. It is used in medicine and food industries. value.

Provided herein are methods for treating schizophrenia or schizoaffective disorder by administering to a subject in need thereof (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester, or an isotopic variant thereof, or a pharmaceutically acceptable salt or polymorph thereof.